Loading...
•
Sep 30, 2022
Arcellx Q3 2022 Earnings Report
Arcellx reported financial results and business progress for Q3 2022.
Key Takeaways
Arcellx reported a net loss of $92.9 million for the third quarter ended September 30, 2022. As of September 30, 2022, Arcellx had cash, cash equivalents, and marketable securities of $280.8 million, which is anticipated to fund its operations for at least the next 12 months.
Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA.
Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 64th ASH Annual Meeting in December.
Company to host a live webcast event with an expert panel of clinicians to discuss the clinical results on Sunday, December 11, 2022.
Began to operationally scale by initiating clinical sites, enrolling patients and dosing our first patients from Lonza, our pivotal cell manufacturer.
Forward Guidance
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...